Qiagen N.V. $QGEN Stake Reduced by Allianz Asset Management GmbH

Key Points

• Allianz Asset Management reduced its Qiagen stake by 55.4% in the second quarter, selling 236,644 shares and retaining 190,386 shares valued at approximately $7.46 million. Institutional investors collectively own about 70% of QGEN.
• Qiagen reported quarterly earnings of $0.62 per share, exceeding the $0.60 analyst consensus, while revenue of $535.04 million also topped estimates. The company reaffirmed fiscal 2026 guidance of approximately $2.43 EPS.
• QGEN shares opened at $42.37, near analysts’ consensus price target of $43.93. Analyst sentiment remains cautious, with a consensus “Hold” rating despite one Strong Buy and four Buy ratings.

Allianz Asset Management GmbH cut its holdings in shares of Qiagen N.V. (NYSE:QGEN - Free Report) by 55.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 190,386 shares of the company's stock after selling 236,644 shares during the period. Allianz Asset Management GmbH owned approximately 0.09% of Qiagen worth $7,461,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. Danske Bank A S acquired a new position in shares of Qiagen in the third quarter worth about $36,000. Manchester Capital Management LLC acquired a new stake in shares of Qiagen in the fourth quarter worth $42,000. Hilltop National Bank purchased a new position in shares of Qiagen during the second quarter valued at $50,000. Global Retirement Partners LLC grew its holdings in shares of Qiagen by 279.9% during the fourth quarter. Global Retirement Partners LLC now owns 1,155 shares of the company's stock valued at $52,000 after buying an additional 851 shares in the last quarter. Finally, Advisory Services Network LLC acquired a new position in Qiagen during the third quarter valued at $64,000. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Stock Performance

QGEN stock opened at $42.37 on Wednesday. The firm has a 50 day moving average of $42.05 and a two-hundred day moving average of $40.25. Qiagen N.V. has a 12 month low of $32.53 and a 12 month high of $57.81. The company has a market capitalization of $8.73 billion, a price-to-earnings ratio of 21.71, a P/E/G ratio of 4.33 and a beta of 0.63. The company has a quick ratio of 2.31, a current ratio of 2.85 and a debt-to-equity ratio of 0.48.

Qiagen (NYSE:QGEN - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share for the quarter, beating analysts' consensus estimates of $0.60 by $0.02. The business had revenue of $535.04 million for the quarter, compared to the consensus estimate of $527.50 million. Qiagen had a net margin of 19.49% and a return on equity of 14.47%. Qiagen's revenue for the quarter was up .2% on a year-over-year basis. During the same quarter last year, the firm earned $0.60 EPS. Qiagen has set its FY 2026 guidance at 2.430- EPS. As a group, equities analysts anticipate that Qiagen N.V. will post 2.43 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on QGEN. Jefferies Financial Group reissued a "buy" rating and issued a $48.00 price target on shares of Qiagen in a research report on Thursday, August 6th. TD Cowen reiterated a "hold" rating on shares of Qiagen in a research note on Wednesday, July 15th. Berenberg Bank set a $45.50 target price on shares of Qiagen and gave the stock a "hold" rating in a research report on Tuesday, July 14th. Weiss Ratings raised shares of Qiagen from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Monday, August 17th. Finally, Kepler Capital Markets set a $38.60 target price on shares of Qiagen and gave the company a "hold" rating in a research note on Thursday, June 25th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $43.93.

About Qiagen

Qiagen NV NYSE: QGEN is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company's solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company's product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.

Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen N.V. (NYSE:QGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.